This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
dna-sequencing: Archive
Is JPMorgan Small Cap Growth Fund A (PGSGX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for PGSGX
PGSGXNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing equity fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is Oppenheimer Global Opportunities A (OPGIX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for OPGIX
OPGIXPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing equity fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is PRIMECAP Odyssey Growth Fund (POGRX) a Strong Mutual Fund Pick Right Now?
by Zacks Equity Research
Mutual Fund Report for POGRX
POGRXNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing equity fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Is PONAX a Strong Bond Fund Right Now?
by Zacks Equity Research
MF Bond Report for PONAX
PONAXPositive Net Change
ad-tech automation autonomous-vehicles batteries bond cell-therapy creator-economy dna-sequencing energy fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna mutual-funds oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Should SPDR Portfolio S&P 500 Value ETF (SPYV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for SPYV
SPYVNegative Net Change JPMNegative Net Change BRK.BNegative Net Change DISNegative Net Change VTVNegative Net Change IWDNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dividend dna-sequencing etf expenses fin-tech furniture-retailers gambling gene-editing gene-therapy holdings home-buying-apps immuno-therapy index market-capitalization medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
by Zacks Equity Research
Sector ETF report for SBIO
SBIONegative Net Change XLVPositive Net Change VHTPositive Net Change
ad-tech apparel automation autonomous-vehicles batteries cell-therapy creator-economy dividend dna-sequencing etf expenses fin-tech furniture-retailers gene-editing gene-therapy hmo holdings home-buying-apps hospitals immuno-therapy index medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media us-equities vaccines
Is SPDR MSCI USA StrategicFactors ETF (QUS) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for QUS
QUSNegative Net Change AAPLNegative Net Change MSFTNegative Net Change JNJPositive Net Change SPYNegative Net Change IVVNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dividend dna-sequencing etf expenses fin-tech furniture-retailers gene-editing gene-therapy holdings home-buying-apps immuno-therapy index medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HBANNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
NOWNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy growth-investing growth-investors growth-stocks high-growth home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
STLDPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna momentum-investor momentum-stocks oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Why Ralph Lauren (RL) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
RLNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna momentum-investor momentum-stocks oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
LDOSNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna momentum-investor momentum-stocks oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
Integra LifeSciences (IART) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IARTNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna momentum-investor momentum-stocks oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked vaccines
After Golden Cross, Repligen (RGEN)'s Technical Outlook is Bright
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
RGENNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy daily-movers dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna moving-average-crossover oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Why This 1 Retail and Wholesale Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.
WMTNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-estimates fin-tech furniture-retailers gene-editing gene-therapy growth-investing home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media vaccines zacks-consensus-estimate zacks-rank
Why VALE S.A. (VALE) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
VALEPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Why Knight-Swift Transportation Holdings (KNX) is a Top Value Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
KNXPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments ride-hailing saas self-driving-cars smart-health social-media top-ranked undervalued-stocks vaccines value-stocks
Yeti (YETI) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Yeti (YETI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
YETINegative Net Change BCNegative Net Change VSTOPositive Net Change ONEWNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Sonic Automotive (SAH) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Sonic Automotive (SAH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
SAHPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Transcat, Inc. (TRNS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Transcat, Inc. (TRNS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TRNSPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Textron (TXT) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Textron (TXT) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TXTPositive Net Change NOCPositive Net Change GDNegative Net Change HIINegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Otis Worldwide (OTIS) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Otis Worldwide (OTIS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
OTISNegative Net Change WSONegative Net Change NXNegative Net Change OCNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Republic Services (RSG) Soars to 52-Week High, Time to Cash Out?
by Zacks Equity Research
Republic Services (RSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
RSGNegative Net Change SRCLNegative Net Change ECOLNegative Net Change CLHNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
CDW (CDW) Hits 52-Week High, Can the Run Continue?
by Zacks Equity Research
CDW (CDW) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CDWNegative Net Change SNXNegative Net Change CACINegative Net Change SSTKPositive Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation
Clean Harbors (CLH) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Clean Harbors (CLH) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
CLHNegative Net Change
ad-tech automation autonomous-vehicles batteries cell-therapy creator-economy dna-sequencing earnings-surprise fin-tech furniture-retailers gene-editing gene-therapy home-buying-apps immuno-therapy medical-devices messenger-rna oncology-screening payments price-change style-scores valuation